

# Annex 1. Country profiles

## Austria

<b>Population (January 2013):</b>	8 451 860
<b>Human development index (2013):</b>	0.881
<b>HAV vaccine recommendations:</b>	HAV vaccination is recommended for children over 2 years of age and adults, particularly if the following indicators apply: <ul style="list-style-type: none"> <li>• 1. children entering institutions</li> <li>• 2. adults at occupational increased risk of exposure</li> <li>• 3. persons with chronic liver disease</li> <li>• 4. contacts of HAV patients or HAV shedders</li> <li>• 5. tourists, occupational travellers, diplomatic service and development assistance in endemic areas.</li> </ul> HAV vaccination is not publicly funded.
<b>Seroprevalence studies by quality score:</b>	score 0:1 study score 1:1 study score 2: 0 studies
<b>Seroprevalence studies timeframe:</b>	1978–1991

A study in 1978 estimated HAV seroprevalence in those under 30 years of age to be over 50%, while one in 1991 estimated that HAV seroprevalence in this age group was 7%. Therefore, it is likely that Austria transitioned from a low to a very low HAV endemicity during the 1980s (Austria\_Figure 1).

**Austria\_Table 1. Hepatitis A endemicity level by time period**


	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

Reported incidence oscillated between 2 and 6/100 000 from 1989 to 2000 (Austria\_Figure 2). The reported incidence based on TESSy data has been under 2/100 000 every year since 2006, although with a slightly increasing trend. This is consistent with a very low endemicity picture.


The susceptibility among adults was high during the 1990s (>70% at 30 years and around 30% at 50 years). Based on these data and the reported incidence below 2/100 000 during the last decade, the susceptibility among adults is nowadays likely to be high.

**Austria\_Figure 1 (panel a).** Summary of seroprevalence in Austria, by age and time period.

Panel a.1: 1975–1989




Panel a.2: 1990–1999




Panel a.3: 2000–2013

No data available

**Austria\_Figure 1 (panel b). Summary of seroprevalence in Austria, by age and time period (1975–2013).**



**Austria\_Figure 2. Reported incidence of hepatitis A, Austria, 1989–2013**



### Bibliography

1. Frisch-Niggemeyer W, Kunz C. [The incidence of antibodies to hepatitis A virus in people from Vienna and certain Austrian provinces (author's transl)]. *Wien Klin Wochenschr.* 1979 Mar 30;91(7):230-3.
2. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, et al. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. *J Travel Med.* 2007;14(3):181-7.
3. Prodingr WM, Larcher C, Solder BM, Geissler D, Dierich MP. Hepatitis A in Western Austria - The epidemiological situation before the introduction of active immunisation. *Infection.* 1994;22(1):53-5.
4. Vutuc C, Kunze M. [Hepatitis A, hepatitis B--incidence of inpatient cases]. *Gesundheitswesen.* 1992 Nov;54(11):649-51.